Skip to main content
    N

    Neumora Therapeutics, Inc. (NMRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.33
    -0.04 (-9.47%)

    Market Cap: $69.43M

    Last updated: Nov 17, 2026 at 4:17 PM ET

    Neumora Therapeutics, Inc. (NMRA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Neumora Therapeutics (NMRA) has a market cap of $69.43M and an enterprise value of $37.08M. Its share count is up 16.10% from a year earlier. It holds $32.35M more cash than debt, 46.60% of its market cap.

    Total Valuation

    Enterprise value is 46.60% below the market cap, as cash exceeds debt.

    Market Cap$69.43M
    Enterprise Value$37.08M
    Latest price (Nov 17, 2026)$0.33

    Key Dates

    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.48% in the quarter ended Sep 30, 2026 and grew 8.51% a year over 2 years.

    Shares Outstanding187.90M
    Shares Change (YoY)+16.10%
    Shares Change (QoQ)+1.48%
    Share Count Growth (2Y CAGR)+8.51%

    Price Statistics

    The stock is down 87.38% over 52 weeks and trades 41.07% below its 50-day average.

    Beta (1Y)0.74
    52-Week Change-87.38%
    1-Month Change-28.83%
    3-Month Change-79.60%
    6-Month Change-79.97%
    Total Return (1Y)-87.38%
    Total Return (3Y CAGR)-69.70%
    Max Drawdown (1Y)-90.68%
    Max Drawdown (3Y)-98.31%
    Sharpe Ratio (1Y)-1.61
    Correlation with SPY (1Y)0.08
    50-Day Average$0.56
    200-Day Average$1.69
    52-Week Range$0.32 to $3.65
    RSI (14 Days)33.2
    Average Volume (20 Days)1.61M

    Price chart

    Financial Position

    Current assets cover 4.08x current liabilities, and total debt is 2.87x shareholder equity.

    Current Ratio4.08x
    Quick Ratio4.08x
    Debt / Equity2.87x
    Interest Coverage-24.82x

    Returns and Efficiency

    Return on invested capital is -260.49% and return on equity is -1026.52% over the last 12 months.

    Return on Equity (ROE)-1026.52%
    Return on Assets (ROA)-200.36%
    Return on Invested Capital (ROIC)-260.49%
    Return on Capital Employed (ROCE)-260.49%
    ROA (5Y Average)-66.89%

    Scores

    NMRA has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Operating Income-$186.94M
    Pretax Income-$190.40M
    Net Income-$190.43M
    EBITDA-$186.46M
    EBIT-$187.17M
    Reported EPS (TTM)-$1.06

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 19.52% of the $95.05M in total assets.

    Cash and Equivalents$85.65M
    Total Debt$53.30M
    Net Cash$32.35M
    Net Cash Per Share$0.17
    Working Capital$71.55M
    Shareholder Equity$18.55M
    Book Value Per Share$0.10
    Total Assets$95.05M
    Total Liabilities$76.50M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$167.33M
    FCF Per Share-$0.89
    Depreciation and Amortization$1.74M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-53.60%
    Tangible Book Per Share Growth (2Y CAGR)-53.60%

    Revenue and profit by year

    Dividends and Yields

    NMRA does not pay a dividend.

    Buyback Yield-67.29%
    Shareholder Yield-67.29%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About NMRA

    What is NMRA's market cap?

    Neumora Therapeutics has a market cap of $69.43M. Its enterprise value, which adds debt and subtracts cash, is $37.08M.

    How many shares of NMRA are outstanding?

    Neumora Therapeutics has 187.90M shares outstanding. The count is up 16.10% from a year earlier.

    Does NMRA pay a dividend?

    No. Neumora Therapeutics does not pay a dividend.

    How much debt does NMRA have?

    Neumora Therapeutics has $53.30M of total debt and $85.65M of cash and equivalents, a net cash position of $32.35M.